English Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil

Revista de Neurología y Neurociencia

  • ISSN: 2171-6625
  • Índice h de la revista: 17
  • Puntuación de cita de revista: 4.43
  • Factor de impacto de la revista: 3.38
Indexado en
  • Abrir puerta J
  • Genamics JournalSeek
  • El Factor de Impacto Global (GIF)
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Directorio de indexación de revistas de investigación (DRJI)
  • OCLC-WorldCat
  • Convocatoria de búsqueda
  • Factor de impacto de revista científica (SJIF)
  • pub europeo
  • Google Académico
  • Laboratorios secretos de motores de búsqueda
Ver más
Comparte esta página

Abstracto

Lack of absorption of extended-release pramipexole in a patient with early parkinson´s disease

Alberto Villarejo, Gema Lizcano, ?lvaro S?nchez-Ferro, Eduardo de Pablo-Fernandez

Pramipexole is a nonergot dopamine agonist indicated for treating Parkinson’s disease (PD) and restless legs syndrome. Pramipexole extended release (ER) is a recently developed once-daily formulation which has demonstrated noninferiority compared with pramipexole immediate release (IR) in the treatment of early [1] and advanced PD [2]. Compared with the immediate release (IR) formulation, the ER formulation offers some advantages, including the potential for improved compliance owing to its simple once-daily dosing regimen and steadier plasma levels over 24 h [3]. According to data from clinical trials, both formulations have a similar digestive absorption with a bioavailability of more than 90%, and the overnight switch from pramipexole IR three times a day to pramipexole ER once daily at unchanged dosage in PD patients has been shown to be successful in more than 80% of patients, with minor adjustments needed in the other patients [4]. Here we report the case of a patient with mild PD, unsuccessfully treated with pramipexole ER due to lack of digestive absorption of the drug.